LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | PI103 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4481 | 5578 | 0.8032 | 0.6384 |
| SK-BR-3 | PLX-4720 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5710 | 5578 | 1.0237 | 1.0435 |
| SK-BR-3 | QL-X-138 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 3605 | 5578 | 0.6462 | 0.3497 |
| SK-BR-3 | QL-XII-47 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 3824 | 5578 | 0.6856 | 0.4221 |
| SK-BR-3 | Radicicol | 0.12 | uM | LJP5 | 72 | hr | 2543 | 2642 | 5578 | 0.4737 | 0.0327 |
| SK-BR-3 | Radicicol | 0.12 | uM | LJP6 | 72 | hr | 2543 | 2396 | 5578 | 0.4295 | -0.0486 |
| SK-BR-3 | Seliciclib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5868 | 5578 | 1.0519 | 1.0954 |
| SK-BR-3 | Ruxolitinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5432 | 5578 | 0.9737 | 0.9517 |
| SK-BR-3 | XL147 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5910 | 5578 | 1.0594 | 1.1092 |
| SK-BR-3 | Saracatinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5463 | 5578 | 0.9793 | 0.9620 |
| SK-BR-3 | Selumetinib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5492 | 5578 | 0.9846 | 0.9717 |
| SK-BR-3 | Sirolimus | 0.12 | uM | LJP6 | 72 | hr | 2543 | 3685 | 5578 | 0.6607 | 0.3763 |
| SK-BR-3 | Sorafenib | 0.12 | uM | LJP6 | 72 | hr | 2543 | 5536 | 5578 | 0.9924 | 0.9859 |
| SK-BR-3 | SU11274 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5996 | 5578 | 1.0749 | 1.1377 |
| SK-BR-3 | Fedratinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5705 | 5578 | 1.0226 | 1.0416 |
| SK-BR-3 | TGX221 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5018 | 5578 | 0.8996 | 0.8155 |
| SK-BR-3 | Torin1 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 1952 | 5578 | 0.3499 | -0.1949 |
| SK-BR-3 | Torin2 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1789 | 5578 | 0.3208 | -0.2484 |
| SK-BR-3 | Tozasertib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 1972 | 5578 | 0.3536 | -0.1882 |
| SK-BR-3 | Trametinib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 4206 | 5578 | 0.7541 | 0.5480 |
| SK-BR-3 | TWS119 | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5472 | 5578 | 0.9809 | 0.9649 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5722 | 5578 | 1.0258 | 1.0474 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP5 | 72 | hr | 2543 | 5358 | 5578 | 0.9606 | 0.9275 |
| SK-BR-3 | Withaferin A | 0.12 | uM | LJP6 | 72 | hr | 2543 | 4999 | 5578 | 0.8961 | 0.8090 |
| SK-BR-3 | WYE-125132 | 0.12 | uM | LJP6 | 72 | hr | 2543 | 2145 | 5578 | 0.3846 | -0.1311 |